Adicet Bio, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ACET, updated each market day.
ACET AI Sentiment
AI predicts Adicet Bio, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Adicet Bio, Inc. Common Stock
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Sector
Exchange
Market Cap
$65,831,352
Cap Tier
Employees
102
Headquarters
BOSTON, MA
Listed Since
Sept. 16, 2020
Website
ACET Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ACET Volatility
Adicet Bio, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
